Titolo: Chemotherapy for Leukemia

Home

/

Specialità

/

Ematologia

/

Chemotherapy for Leukemia

Novel Drugs and Treatment

Editore

Springer

Anno

2017

Pagine

361

ISBN

9789811033308

I prezzi indicati possono subire variazioni poiché soggetti all'oscillazione dei cambi delle valute e/o agli aggiornamenti effettuati dagli Editori.

Dettagli Indice Recensioni (0)

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells.

This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.

An Overview

Ueda, Takanori

Pages 1-7
Imatinib: Basic Results

Tsukahara, Fujiko (et al.)

Pages 11-31
Imatinib: Clinical Pharmacology and Therapeutic Results

Ohnishi, Kazunori

Pages 33-54
Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs

Kimura, Shinya

Pages 55-75
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokinetics

Sugiyama, Katsuki

Pages 79-98

Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results

Fukuhara, Suguru (et al.)

Pages 99-122
Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results

Usui, Noriko

Pages 123-136
Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results

Takada, Satoru

Pages 137-149
Mogamulizumab in Adult T-Cell Leukemia/Lymphoma

Ogura, Michinori

Pages 151-163
FLT3 Inhibitors

Kiyoi, Hitoshi

Pages 167-179
Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene

Asou, Norio

Pages 183-211
The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL)

Kizaki, Masahiro

Pages 213-220
Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results

Emi, Nobuhiko

Pages 221-238
Nelarabine

Yamauchi, Takahiro (et al.)

Pages 241-250
Forodesine

Yamauchi, Takahiro (et al.)

Pages 251-260
Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology

Parker, William B. (et al.)

Pages 261-286
Clinical Use of Clofarabine for Adults and Children with Leukemia

McCloskey, James (et al.)

Pages 287-309
Re-emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects

Sarkisjan, Dzjemma (et al.)

Pages 311-326
Epigenetic Regulator, Re-emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results

Sato, Shinya (et al.)

Pages 327-340
Therapies Targeting Leukemic Stem Cells

Maekawa, Taira

Pages 343-361